TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

TEYRO LABS

OncologyGastroenterology
Generics

TEYRO LABS is a generic drug manufacturer focused on Oncology, Gastroenterology. Key products include GEMCITABINE HYDROCHLORIDE.

2007
Since
4
Drugs
-
Trials
37
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

CARBOPLATIN 2026-02-04
CAPECITABINE 2026-01-27
Labeling
GEMCITABINE HYDROCHLORIDE 2025-09-16
Labeling
GEMCITABINE HYDROCHLORIDE 2025-08-04
Labeling
GEMCITABINE HYDROCHLORIDE 2025-08-04
Labeling
GEMCITABINE HYDROCHLORIDE 2025-07-24
Labeling
GEMCITABINE HYDROCHLORIDE 2025-07-09
Labeling
CAPECITABINE 2025-06-17
Labeling
CAPECITABINE 2025-06-17
Labeling
CAPECITABINE 2025-04-09
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 50%
1 drugs
Gastroenterology 50%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology
Takeda big-pharma
Oncology, Gastroenterology
Gilead Sciences biotech
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology